10:45 AM EST, 02/24/2026 (MT Newswires) -- Sarepta Therapeutics ( SRPT ) said Tuesday that Roche's Chugai Pharmaceutical has launched Elevidys gene therapy in Japan to treat children 3 years old to under 8 years old with Duchenne muscular dystrophy.

Sarepta said it will be entitled to a $40 million milestone payment tied to the first commercial sale of Elevidys in Japan.

The commercial launch followed Elevidys' reimbursement listing on Japan's National Health Insurance price list, Sarepta said.

Under Sarepta's collaboration deal with Roche Group, Roche is responsible for the product's regulatory process and commercialization outside the US, with Chugai also in charge of postmarketing clinical studies and monitoring in Japan, Sarepta said.

Shares of Sarepta were 3.8% higher in recent trading Tuesday.

Price: 18.82, Change: +0.70, Percent Change: +3.84